Pharmacoeconomic analysis of paricalcitol and calcitriol in the treatment of secondary hyperparathyroidism in haemodialysis: impact of hospitalisations and survival

References

• U.S. Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2004
   Google Scholar
• Bricker NS, Slatopolsky E, Reiss E, et al. Calcium, phosphorus and bone in renal disease and transplantation. Archives of Internal Medicine 1969; 123: 543–553
   PubMedGoogle Scholar
• De Boer IH, Gorodetskaya I, Young B, et al. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. Journal of the American Society of Nephrology 2002; 13: 2762–2769
   PubMedGoogle Scholar
• Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure—an evolving disorder. Kidney International 1993; 43: 436–442
   PubMed Web of Science ®Google Scholar
• Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. American Journal of Kidney Diseases 2000; 36: 1115–1121
   PubMed Web of Science ®Google Scholar
• Rix M, Andreassen H, Eskildsen P, et al. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic kidney failure. Kidney International 1999; 56: 1084–1093
   PubMed Web of Science ®Google Scholar
• Tsuchihashi K, Takizawa H, Torii T, et al. Hypoparathyroidism potentiates the cardiovascular complications through disturbed calcium metabolism. Possible risk of vitamin D analog administration in dialysis patients with end-stage renal disease. Nephron 2000; 84: 13–20
   PubMed Web of Science ®Google Scholar
• Goodman W, Goldin J, Kuizon BD, et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. New England Journal of Medicine 2000; 342: 1478–1483
   PubMed Web of Science ®Google Scholar
• Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney International 2006; 69: 33–43
   PubMed Web of Science ®Google Scholar
• Silver J, Russell J, Sherwood LM. Regulation by vitamin D metabolites of messenger RNA for preparathyroid hormone in isolated bovine parathyroid cells. Proceedings of the National Academy of Sciences USA 1985; 82: 4270–4273
   PubMed Web of Science ®Google Scholar
• Ramirez JA, Emmett M, White MG, et al. The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney International 1986; 30: 753–759
   PubMed Web of Science ®Google Scholar
• Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. American Journal of Kidney Diseases 2000; 35: 1226–1235
   PubMed Web of Science ®Google Scholar
• Finch JL, Brown AJ, Slatopolsky E. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. Journal of the American Society of Nephrology 1999; 10: 980–985
   PubMed Web of Science ®Google Scholar
• Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. Journal of Laboratory and Clinical Medicine 2002; 139: 279–284
   PubMed Web of Science ®Google Scholar
• Martin K, Gonzalez E, Gellens M, et al. 19-Nor-1-α-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. Journal of the American Society of Nephrology 1998; 9: 1427–1432
   PubMed Web of Science ®Google Scholar
• Goldenberg MM. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. Clinical Therapeutics 1999; 21: 432–441
   PubMed Web of Science ®Google Scholar
• Lindberg J, Martin KJ, Gonzalez EA, et al. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clinical Nephrology 2001; 56: 315–323
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Cozzolino M, Finch JL. Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney International 2002; 62: 1277–1284
   PubMed Web of Science ®Google Scholar
• Nakane M, Fey TA, Dixon DB, et al. Differential effects of vitamin D analogs on bone formation and resorption. Journal of Steroid Biochemistry and Molecular Biology 2006; 98: 72–77
   PubMed Web of Science ®Google Scholar
• Teng M, Wolf M, Ofsthun N, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. Journal of the American Society of Nephrology 2005; 16: 1115–1125
   PubMed Web of Science ®Google Scholar
• Dobrez DG, Mathes A, Amdahl M, et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrology, Dialysis, Transplantation 2004; 19: 1174–1181
   PubMed Web of Science ®Google Scholar
• Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. New England Journal of Medicine 2003; 349: 446–456
   PubMed Web of Science ®Google Scholar
• Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney International 2003; 63: 1483–1490
   PubMed Web of Science ®Google Scholar
• Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. American Journal of Kidney Diseases 2001; 38((Suppl. 5))S45–S50
   PubMed Web of Science ®Google Scholar
• Mittman N, Khanna R, Rani S, et al. Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: a single-center crossover study. Kidney International Supplement 2006, (104): S64–S67
   Google Scholar
• Summary of 2005 Physician Schedule Final Rule. Available at: http://www.aapgpa.org/advocacy/1104_hpa_summary.pdf [accessed 7 June 2007].
   Google Scholar
• 2006 The DRG Handbook. Comparative Clinical and Financial Benchmarks, Solucient, LLC
   Google Scholar
• Marx SE, Brown MD, Ashraf T, et al. Evaluation of annualized dosing ratio of paricalcitol to calcitriol in hemodialysis patients. Journal of the American Society of Nephrology 2004; 15: 862A
   Google Scholar
• United States Department of Labor. Available at: http://www.bls.gov/ro5/cpimpls.htm [accessed 17 October 2006].
   Google Scholar
• Healthcare Cost & Utilization Project 2004 National Statistics—Principal Diagnosis Only. Available at: http://hcup.ahrq.gov/HCUPnet.jsp [accessed 16 October 2006].
   Google Scholar
• Wolf M, Teng M, Thadhani R. Paricalcitol, calcitriol and survival of patients undergoing hemodialysis. New England Journal of Medicine 2003; 349: 1771–1772
   Google Scholar
• Berger ML, Bingefors K, Hedblom EC, et al. Health care cost, quality, and outcomes. International Society for Pharmacoeconomics and Outcomes Research 2003; 241
   Google Scholar
• Eastman RC, Javitt JC, Herman WH. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997; 20: 735–744
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. Journal of the American Medical Association 1996; 276: 1409–1415
   PubMed Web of Science ®Google Scholar
• Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. British Medical Journal 1995; 311: 1595–1599
   PubMed Web of Science ®Google Scholar
• Lawrence WF, Grist TM, Brazy PC. Magnetic resonance angiography in progressive renal failure: a technology assessment. American Journal of Kidney Diseases 1995; 25: 701–709
   PubMed Web of Science ®Google Scholar
• Harvard CEA Registry. Standardizing the methods and practices of cost-effectiveness analysis. Available at: http://www.hcra.harvard.ede/pdf/preferecescores.pdf [accessed 11 Feb 2005].
   Google Scholar
• Robbins JD, Kim JJ, Zdon G, et al. Resource use and patient care associated with chronic kidney disease in a managed care setting. Journal of Managed Care Pharmacy 2003; 9: 238–447
   PubMedGoogle Scholar
• United States Renal Data System. Cardiovascular report. Available at: http://www.usrds.org/adr.htm [accessed 20 May 2005].
   Google Scholar
• St Peter WL, Khan SS, Ebben JP, et al. Chronic kidney disease. The distribution of healthcare dollars. Kidney International 2004; 66: 313–321
   PubMed Web of Science ®Google Scholar
• Drueke TB. Aspects of cardiovascular burden in pre-dialysis patients. Nephron 2000; 85((Suppl. 1))9–14
   PubMedGoogle Scholar
• Capomolla S, Febo O, Ceresa M, et al. Cost/utility ratio in chronic heart failure: comparison between heart failure management program delivered by day-hospital and usual care. Journal of the American College of Cardiology 2002; 40: 1259–1266
   PubMed Web of Science ®Google Scholar
• Trentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney International 2006; 70: 1858–1856
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Juwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney International 2006; 70: 771–780
   PubMed Web of Science ®Google Scholar
• Drummond MF, Davies L. Economic analysis alongside clinical trials. Revisiting the methodological issues. International Journal of Technology Assessment in Health Care 1991; 7: 561–573
   PubMedGoogle Scholar